Trials / Completed
CompletedNCT02294058
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,346 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Capsules for oral administration once a day |
| DRUG | Interferon beta-1a | Administered by intramuscular injection once a week |
| DRUG | Placebo to ozanimod | Matching placebo capsules administered orally once a day |
| DRUG | Placebo to interferon beta-1a | Placebo intramuscular injection once a week |
Timeline
- Start date
- 2014-12-03
- Primary completion
- 2016-12-22
- Completion
- 2016-12-22
- First posted
- 2014-11-19
- Last updated
- 2020-11-25
- Results posted
- 2020-11-25
Locations
224 sites across 25 countries: United States, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Latvia, Lithuania, Moldova, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02294058. Inclusion in this directory is not an endorsement.